172 related articles for article (PubMed ID: 8297795)
1. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
Roland J; Morello D
Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
[TBL] [Abstract][Full Text] [Related]
2. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
3. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
4. The 5' and 3' non-coding sequences of the c-myc gene, required in vitro for its post-transcriptional regulation, are dispensable in vivo.
Morello D; Lavenu A; Pournin S; Babinet C
Oncogene; 1993 Jul; 8(7):1921-9. PubMed ID: 8510935
[TBL] [Abstract][Full Text] [Related]
5. The cis-acting elements known to regulate c-myc expression ex vivo are not sufficient for correct transcription in vivo.
Lavenu A; Pournin S; Babinet C; Morello D
Oncogene; 1994 Feb; 9(2):527-36. PubMed ID: 8290263
[TBL] [Abstract][Full Text] [Related]
6. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc.
Haupt Y; Harris AW; Adams JM
Oncogene; 1992 May; 7(5):981-6. PubMed ID: 1570158
[TBL] [Abstract][Full Text] [Related]
7. The transgenic window on lymphoid malignancy.
Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S
Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688
[TBL] [Abstract][Full Text] [Related]
8. Increased transcription of the E mu-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein.
Colley SM; Tilbrook PA; Klinken SP
Oncogene; 1997 Jun; 14(22):2735-9. PubMed ID: 9178772
[TBL] [Abstract][Full Text] [Related]
9. Different regulation of class I gene expression in the adult mouse and during development.
Drezen JM; Nouvel P; Babinet C; Morello D
J Immunol; 1992 Jul; 149(2):429-37. PubMed ID: 1624790
[TBL] [Abstract][Full Text] [Related]
10. Hemopoietic neoplasms in lethally irradiated mice repopulated with bone marrow cells carrying the human c-myc oncogene: a repopulation assay.
Hirabayashi Y; Inoue T; Suda Y; Aizawa S; Ikawa Y; Kanisawa M
Exp Hematol; 1992 Feb; 20(2):167-72. PubMed ID: 1544384
[TBL] [Abstract][Full Text] [Related]
11. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligodeoxynucleoside methylphosphonate inhibition of mouse c-myc p65 protein expression in E mu-c-myc transgenic mice.
Wickstrom E; Bacon TA; Wickstrom EL; Werking CM; Palmiter RD; Brinster RL; Sandgren EP
Nucleic Acids Symp Ser; 1991; (24):151-4. PubMed ID: 1841270
[TBL] [Abstract][Full Text] [Related]
14. Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse.
Huang CY; Bredemeyer AL; Walker LM; Bassing CH; Sleckman BP
Eur J Immunol; 2008 Feb; 38(2):342-9. PubMed ID: 18196519
[TBL] [Abstract][Full Text] [Related]
15. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
Strasser A; Harris AW; Bath ML; Cory S
Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704
[TBL] [Abstract][Full Text] [Related]
16. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1988; 3(3):271-9. PubMed ID: 3144697
[TBL] [Abstract][Full Text] [Related]
17. Lymphoproliferative syndrome associated with c-myc expression driven by a class I gene promoter in transgenic mice.
Morello D; Lavenu A; Bandeira A; Portnoi D; Gaillard J; Babinet C
Oncogene Res; 1989; 4(2):111-25. PubMed ID: 2654814
[TBL] [Abstract][Full Text] [Related]
18. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of v-myc/v-raf-transformed murine fetal thymocyte cell lines.
Taubenberger JK; Reid AH; Izon D; Boehme SA
Cell Immunol; 1996 Jul; 171(1):41-7. PubMed ID: 8754860
[TBL] [Abstract][Full Text] [Related]
20. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
